AGUIRRE JARRAD MATTIEU enters LYELL IMMUNOPHARMA, INC. with 20.28K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 9/10/2026ACC: 0002150331-26-000001
Officer· Chief Medical Officer
Since Sep 2026
20.28K
Baseline shares
100% direct
20.28K
Direct ownership
1 position
96.25K
Derivative underlying
3 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned20.28K
Total
20.28K direct20.28K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 20.28K | Direct |
| Total | 20.28K | 20.28K direct |
Derivative Holdings3
Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
46.25K
Shares owned
N/A
Exercise price
11.64
Expiration
—
Exercise window
—
Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
15K
Shares owned
N/A
Exercise price
19.20
Expiration
—
Exercise window
—
Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
35K
Shares owned
N/A
Exercise price
23.71
Expiration
—
Exercise window
—
Total
Underlying
96.25K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Option (right to buy) Direct | Common Stock | 11.64 | — | — | 46.25K | N/A |
| Option (right to buy) Direct | Common Stock | 19.20 | — | — | 15K | N/A |
| Option (right to buy) Direct | Common Stock | 23.71 | — | — | 35K | N/A |
| Total | 96.25K | 0.00 | ||||